Marker utility for combination therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Melanoma is a heterogeneous disease for which monotherapies are likely to fail in the majority of patients due to genomic variations between individuals. Novel treatments, such as vemurafenib and ipilimumab, offer clinical promise in metastatic melanoma and the increased potential for combined therapeutic strategies, necessary given the differences in response between patients. Together with these new approaches, the development of clinically relevant biomarkers that predict treatment outcomes are required to ensure these new therapies are targeted at those patients most likely to benefit. Here we review the utility of some potential biomarkers of treatment response in patients with metastatic melanoma.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
Pages97-115
Number of pages19
Volume1102
DOIs
Publication statusPublished - 2014

Publication series

NameMethods in Molecular Biology
Volume1102
ISSN (Print)10643745

    Fingerprint

Keywords

  • Anti-PD1
  • Biomarkers
  • BRAF inhibitors
  • Combination therapy
  • Immune therapy
  • Ipilimumab
  • Metastatic melanoma
  • Molecular profiling
  • Vemurafenib

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Simeone, E., Grimaldi, A. M., & Ascierto, P. A. (2014). Marker utility for combination therapy. In Methods in Molecular Biology (Vol. 1102, pp. 97-115). (Methods in Molecular Biology; Vol. 1102). https://doi.org/10.1007/978-1-62703-727-3_7